Drugs / it-hMSC
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04590118 | Apr 2021 → Apr 2023 | ischemic stroke | Jiuzhitang Maker (Beijing) Cell Technology Co.,Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT04953663 | Jan 2021 → Jan 2022 | ischemic stroke | Peking University Third Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | it-hMSC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04953663 ↗ |
| Modality | Cell therapy | “Allogeneic mesenchymal stem cells have been used in many clinical studies for different diseases.” NCT04590118 ↗ |
| Route | Intravenous | “Single intravenous infusion of it-hMSC for ischemic stroke patients” NCT04590118 ↗ |